Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T‐lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia

Documenti analoghi

• Philadelphia chromosome‐like B‐acute lymphoblastic leukemia and disseminated juvenile xanthogranulomatosis with shared KRAS mutation
  di: Jinjun Cheng, et al.
  Pubblicazione: (2024)
• BRAF/MEK inhibitors use to treat ventriculoperitoneal shunt‐associated ascites in pediatric low‐grade gliomas
  di: Nisreen Amayiri, et al.
  Pubblicazione: (2024)
• Treatment of a pediatric patient with concurrent neuroblastoma and acute lymphoblastic leukemia
  di: Megan M. Lilley, et al.
  Pubblicazione: (2024)
• Outcomes for pediatric acute lymphoblastic leukemia patients with intestinal perforation
  di: Gustavo de Oliveira Canedo, et al.
  Pubblicazione: (2024)
• KIT ‐mutated pediatric core‐binding factor systemic mastocytosis‐acute myeloid leukemia treated with avapritinib and decitabine
  di: Irtiza N. Sheikh, et al.
  Pubblicazione: (2024)